Form 10-Q Intra-Cellular Therapies For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Intra-Cellular Therapies (ITCI) PT Raised to $79 at Goldman Sachs
October 30, 2024 4:38 PM EDTGoldman Sachs analyst Corinne Jenkins raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $79.00 (from $74.00) while maintaining a Neutral rating.
The analyst comments "Focus remains on commercial execution ahead of MDD launch. ITCI reported 3Q24 revenues of $175.4M, slightly higher than FactSet consensus ($172.3M, +2%) and in-line with GS estimate ($175.2M, 0%). The company also modestly raised and narrowed the range... More
